Table 4.

Bradycardia, permanent pacemaker implantation, atrial fibrillation, and mortality after HTX

Parameter	No use of amiodarone before HTX (n=412)	Acute use of amiodarone before HTX (n=23)	Chronic use of amiodarone before HTX (n=95)	P-value
Bradycardia,^ week 1 after HTX	9 of 412 (2.2%)	0 of 23 (0.0%)	0 of 95 (0.0%)	0.2695
Bradycardia,^ week 2 after HTX	3 of 412 (0.7%)	0 of 23 (0.0%)	1 of 95 (1.1%)	0.8644
Bradycardia,^ week 3 after HTX	4 of 412 (1.0%)	0 of 23 (0.0%)	1 of 95 (1.1%)	0.8894
Bradycardia,^ week 4 after HTX	3 of 412 (0.7%)	0 of 23 (0.0%)	1 of 95 (1.1%)	0.8644
30-Day follow-up PPM implantation	3 of 412 (0.7%)	0 of 23 (0.0%)	1 of 95 (1.1%)	0.8644
30-Day follow-up occurrence of AF	56 of 412 (13.6%)	3 of 23 (13.0%)	2 of 95 (2.1%)	0.0065*
30-Day follow-up mortality	40 of 412 (9.7%)	3 of 23 (13.0%)	9 of 95 (9.5%)	0.8656
1-Year follow-up PPM implantation	5 of 405 (1.2%)	0 of 23 (0.0%)	1 of 92 (1.1%)	0.8628
1-Year follow-up mortality	88 of 405 (21.7%)	5 of 23 (21.7%)	20 of 92 (21.7%)	1.0000
2-Year follow-up PPM implantation	8 of 401 (2.0%)	0 of 23 (0.0%)	2 of 90 (2.2%)	0.7797
2-Year follow-up mortality	104 of 401 (25.9%)	5 of 23 (21.7%)	22 of 90 (24.4%)	0.8763
5-Year follow-up PPM implantation	10 of 348 (2.9%)	0 of 20 (0.0%)	2 of 78 (2.6%)	0.7400
5-Year follow-up mortality	130 of 348 (37.4%)	8 of 20 (40.0%)	24 of 78 (30.8%)	0.5174
Overall follow-up PPM implantation	18 of 412 (4.4%)	1 of 23 (4.3%)	3 of 95 (3.2%)	0.8664
Overall follow-up mortality	206 of 412 (50.0%)	10 of 23 (43.5%)	38 of 95 (40.0%)	0.1936

Notes:

^{^}Bradycardia defined as mean weekly heart rate <60 beats per minute.

^*Statistically significant (P<0.05).

Abbreviations: HTX, heart transplantation; PPM, permanent pacemaker; AF, atrial fibrillation.